Evidence map›Paper›PMID 38205210›Full record

ArticleTranslational lung cancer research2023

An advanced NSCLC patient with

Hui Li, Jingjing Liu, Shaowei Lan, Rui Zhong, Yanan Cui, Petros Christopoulos, Erin L Schenk, Takaaki Sasaki, Ying Cheng

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Hui LiTranslational Oncology Research Lab, Jilin Cancer Hospital, Changchun, China.
Jingjing LiuDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Shaowei LanTranslational Oncology Research Lab, Jilin Cancer Hospital, Changchun, China.
Rui ZhongTranslational Oncology Research Lab, Jilin Cancer Hospital, Changchun, China.
Yanan CuiDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Petros ChristopoulosDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Erin L SchenkDivision of Medical Oncology, Department of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
Takaaki SasakiDepartment of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Japan.
Ying ChengTranslational Oncology Research Lab, Jilin Cancer Hospital, Changchun, China.
Jilin Province Tumor Hospital · CNAsahikawa Medical University · JPUniversity Hospital Heidelberg · DEUniversity of Colorado Anschutz Medical Campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anaplastic lymphoma kinase ( Case Description: We reported a female patient diagnosed with stage IVB lung adenocarcinoma (LUAD) harboring a novel Conclusions: We have reported an advanced NSCLC patient with a complex nonreciprocal/reciprocal

Indexed as

case reportcombined treatmentnonreciprocal/reciprocal ALK translocationNon-small cell lung cancer (NSCLC)ring finger protein 144A (RNF144A)

Identifiers

PMID38205210
PMCPMC10774998
OpenAlexW4390238063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.